Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma

<div>Lesions of the right thorax before (left) and six months after (right) radiation showing excellent response to radiation (66–76 Gy) with concurrent and adjuvant vismodegib: (anterior upper (a); anterior lower (b); lower neck (c); and back (d)). All lesions completely resolved with complete skin closure, including an additional left back lesion (not shown).</div>

Case Reports in Dermatological Medicine

fig2

Figure 2

Figure 2: Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma 

Figure 2 | Upfront Radiotherapy with Concurrent and Adjuvant Vismodegib Is Effective and Well-Tolerated in a Patient with Advanced, Multifocal Basal Cell Carcinoma 